methyl 4-((((1H-benzo[d]imidazol-2-yl)methyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)-3-(aminomethyl)benzoate | 422284-01-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: methyl 4-((((1H-benzo[d]imidazol-2-yl)methyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)-3-(aminomethyl)benzoate
• 英文别名: methyl 3-(aminomethyl)-4-[[1H-benzimidazol-2-ylmethyl(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzoate
• CAS: 422284-01-3
• 化学式: C₂₇H₂₉N₅O₂
• 分子量: 455.56
• InChiKey: HDKXIWYHUZPVLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  97.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  tert-butyl 2-(((2-aminomethyl-4-(methoxycarbonyl)benzyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)-1H-benzo[d]imidazole-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以39 mg的产率得到methyl 4-((((1H-benzo[d]imidazol-2-yl)methyl)(5,6,7,8-tetrahydroquinolin-8-yl)amino)methyl)-3-(aminomethyl)benzoate
  参考文献：
  名称：

  Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication

  摘要：

  An early lead from the AMD070 program was optimized and a structure-activity relationship was developed for a novel series of heterocyclic containing compounds. Potent CXCR4 antagonists were identified based on anti-HIV-1 activity and Ca(2+) flux inhibition that displayed good pharmacokinetics in rat and dog. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.11.023

文献信息

• Methods to mobilize progenitor/stem cells
  申请人：Bridger Gary

  公开号：US20050043367A1

  公开（公告）日：2005-02-24

  Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z′  (1) or pharmaceutically acceptable salt thereof wherein Z is of the formula wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1-20 atoms, Z′ is of the formula —Ar(Y) j ; wherein Ar is an aromatic or heteroaromatic moiety, and each Y is independently a non-interfering substituent and j is 0-3; and “linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.

  本文揭示了利用与趋化因子受体CXCR4结合的化合物来提高动物主体和干细胞计数的方法。这些化合物的优选实施方式为式Z-连接-Z' (1)或其药用盐，其中Z的式为其中A包括至少含有一个N的单环或双环融合环系统，B为H或含有1-20个原子的有机基团，Z'的式为-Ar(Y)j；其中Ar为芳香或杂芳基团，每个Y独立地表示非干扰取代基，j为0-3；“连接物”代表键，烷基（1-6C）或可能包含芳基，融合芳基，含有在烷基链中的氧原子，或可能含有酮基团或氮或硫原子。
• Chemokine receptor binding heterocyclic compounds
  申请人：——

  公开号：US20030028022A1

  公开（公告）日：2003-02-06

  Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.

  本发明揭示了调节趋化因子受体活性的化合物。这些化合物通常为包含四氢喹啉和苯并咪唑的三级胺。
• CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS
  申请人：ANORMED INC.

  公开号：EP1317451A1

  公开（公告）日：2003-06-11
• METHODS TO MOBILIZE PROGENITOR/STEM CELLS
  申请人：ANORMED INC.

  公开号：EP1631307A1

  公开（公告）日：2006-03-08
• EP1631307A4
  申请人：——

  公开号：EP1631307A4

  公开（公告）日：2008-03-26